Review article · 2012 · Open access

Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis

Jianping Zhang, Juan A. Gallego, Delbert G. Robinson, Anil K. Malhotra, John Michael Kane, Christoph Ulrich Correll

The International Journal of Neuropsychopharmacology, 16(6), 1205–1218 · Published 3 December 2012 · DOI 10.1017/s1461145712001277

Open PDFView at the publisherCite this paper

In brief

“Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis” is a 2012 review article by Jianping Zhang and 5 co-authors, published in The International Journal of Neuropsychopharmacology. OpenAlex counts 391 citations as of 20 November 2026, which puts it in the top 1% of works published in 2012 by citations. It is open access: the full text is free to read at The International Journal of Neuropsychopharmacology.

Citations
391
Most cited in
2019 (44)
Field-weighted impact
1.97
References
54
Authors
6

Abstract

Because early treatment choice is critical in first-episode schizophrenia-spectrum disorders (FES), this meta-analysis compared efficacy and tolerability of individual second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) in FES. We conducted systematic literature search (until 12 December 2010) and meta-analysis of acute, randomized trials with ≥1 FGA vs. SGA comparison; patients in their first episode of psychosis and diagnosed with schizophrenia-spectrum disorders; available data for psychopathology change, treatment response, treatment discontinuation, adverse effects, or cognition. Across 13 trials (n = 2509), olanzapine (seven trials) and amisulpride (one trial) outperformed FGAs (haloperidol: 9/13 trials) in 9/13 and 8/13 efficacy outcomes, respectively, risperidone (eight trials) in 4/13, quetiapine (one trial) in 3/13 and clozapine (two trials) and ziprasidone (one trial) in 1/13, each. Compared to FGAs, extrapyramidal symptom (EPS)-related outcomes were less frequent with olanzapine, risperidone and clozapine, but weight gain was greater with clozapine, olanzapine and risperidone. Pooled SGAs were similar to FGAs regarding total psychopathology change, depression, treatment response and metabolic changes. SGAs significantly outperformed FGAs regarding lower treatment discontinuation, irrespective of cause, negative symptoms, global cognition and less EPS and akathisia, while SGAs increased weight more (p < 0.05-0.01). Results were not affected by FGA dose or publication bias, but industry-sponsored studies favoured SGAs more than federally funded studies. To summarize, in FES, olanzapine, amisulpride and, less so, risperidone and quetiapine showed superior efficacy, greater treatment persistence and less EPS than FGAs. However, weight increase with olanzapine, risperidone and clozapine and metabolic changes with olanzapine were greater. Additional FES studies including broader-based SGAs and FGAs are needed.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhang, J., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2012). Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. The International Journal of Neuropsychopharmacology, 16(6), 1205–1218. https://doi.org/10.1017/s1461145712001277

MLA 9

Zhang, Jianping, et al. “Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.” The International Journal of Neuropsychopharmacology, vol. 16, no. 6, 2012, pp. 1205–1218. https://doi.org/10.1017/s1461145712001277.

Chicago

Zhang, Jianping, Juan A. Gallego, Delbert G. Robinson, Anil K. Malhotra, John Michael Kane, and Christoph Ulrich Correll. 2012. “Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.” The International Journal of Neuropsychopharmacology 16 (6): 1205–1218. https://doi.org/10.1017/s1461145712001277.

Harvard

Zhang, J. et al. (2012) ‘Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis’, The International Journal of Neuropsychopharmacology, 16(6), pp. 1205–1218. doi:10.1017/s1461145712001277.

IEEE

J. Zhang, J. A. Gallego, D. G. Robinson, A. K. Malhotra, J. M. Kane, and C. U. Correll, “Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis,” The International Journal of Neuropsychopharmacology, vol. 16, no. 6, pp. 1205–1218, 2012, doi: 10.1017/s1461145712001277.

BibTeX

@article{zhang2012efficacy,
  title     = {{Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis}},
  author    = {Zhang, Jianping and Gallego, Juan A. and Robinson, Delbert G. and Malhotra, Anil K. and Kane, John Michael and Correll, Christoph Ulrich},
  journal   = {The International Journal of Neuropsychopharmacology},
  year      = {2012},
  volume    = {16},
  number    = {6},
  pages     = {1205--1218},
  doi       = {10.1017/s1461145712001277},
  url       = {https://doi.org/10.1017/s1461145712001277}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20172727
20182323
20194444
20203131
20213030
20223737
20233131
20244141
20253434
20261515

Its field-weighted citation impact is 1.97: it has been cited 1.97 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • first-episode psychosis
  • first-episode schizophrenia
  • atypical antipsychotics
  • typical antipsychotics
  • olanzapine
  • amisulpride
  • risperidone
  • quetiapine

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Zhang, J., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2012). Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. The International Journal of Neuropsychopharmacology, 16(6), 1205–1218. https://doi.org/10.1017/s1461145712001277

How many times has this paper been cited?

391 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The International Journal of Neuropsychopharmacology: sign in and open the PDF from this page.

Who wrote this paper?

Jianping Zhang, Juan A. Gallego, Delbert G. Robinson, Anil K. Malhotra, John Michael Kane, Christoph Ulrich Correll.

What is the DOI of this paper?

10.1017/s1461145712001277, permanently at https://doi.org/10.1017/s1461145712001277. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.